ERBB2 and breast carcinoma: In MDA-MB-231 breast cancer cells, which are HER-2-negative, interplay with HER-2/neu cannot account for the observed reduction in proliferation, indicating that growth inhibition at supraphysiological leptin concentrations is HER-2/neu independent.